The pricing was set at SEK 545.00, achieving a limited 7.1% discount to last close, despite challenging market conditions and following a strong stock rally of +120% over the last 12 months. The total deal size amounted 2,000,000 shares, equivalent to SEK 1,090m and representing 3.6% of issued share capital.

The book was multiple times oversubscribed, with strong support from international and local investors, primarily consisting of new investors and supported by existing holders.

The net proceeds are intended to be used to:

• Strengthen Camurus’ ability to acquire commercial and late-stage development assets that are complementary to the CAM2029 portfolio within rare diseases and/or current business in opioid dependence treatment
• Accelerate the build-up of the Company’s U.S. commercial, marketing, market access and medical affairs organization for CAM2029 and commercial readiness for anticipated launches in neuroendocrine tumours and polycystic liver disease
• Develop and enhance manufacturing capacity to support growth and expansion in existing and future therapeutic areas, and secure long-term sourcing and supply

This marks the third fundraise for Nordic BioPharma over the past few months including Calliditas Therapeutic’s EUR 92m Debt Financing and Egetis Therapeutic’s SEK 462m Combined Equity and Debt Offering, demonstrating once again our unique ability to raise capital for European healthcare companies in a highly competitive fundraising environment.